Inflammatory Bowel Diseases最新文献

{"title":"Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds.","authors":"Joëlle St-Pierre, Maxime Delisle, Yusuke Miyatani, Katherine Falloon, Kenneth Ernest-Suarez, Baldeep Pabla, Hien Huynh, Brooke Maracle, Janice Y Kung, Noa Cleveland, David T Rubin, Michael Dolinger, Kerri Novak, Oriana Damas, Gil Y Melmed, Cathy Lu, Amelia Kellar","doi":"10.1093/ibd/izag052","DOIUrl":"10.1093/ibd/izag052","url":null,"abstract":"<p><strong>Background: </strong>Transmural healing (TMH) indicates resolution of inflammation in all bowel wall layers and is an emerging therapeutic target in Crohn's disease (CD). Standardized sonographic criteria for TMH and early improvement, termed Transmural Response (TMR), have not been established. This systematic review synthesizes published definitions to provide an up-to-date overview of the current evidence base for intestinal ultrasound (IUS)-based assessment in CD.</p><p><strong>Methods: </strong>This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Comprehensive searches of databases identified full-text articles that pre-specified TMH, TMR or normal/abnormal bowel on trans-abdominal IUS in pediatric or adult participants with CD. Definitions were summarized descriptively.</p><p><strong>Results: </strong>Eighty-three full-text studies (8033 patients) met eligibility criteria; 39 (47%) defined TMH and 22 (27%) defined TMR. TMH definitions most often included bowel-wall thickness (BWT) ≤ 3mm (31/39, 79%), absent or minimal Doppler flow (25/39, 64%), and preserved bowel wall stratification (10/39, 26%). All TMR definitions required BWT reduction, but thresholds varied (absolute ≥ 1 mm or relative ≥ 25% in 16/22, 73%). Nine studies (9/22, 41%) also required Doppler flow improvement and 4/22 (18%) included additional criteria. Pediatric-specific criteria were reported in 2 TMH and one TMR studies, extrapolating from adult BWT values. Heterogeneity precluded quantitative pooling.</p><p><strong>Conclusions: </strong>Standardized IUS definitions of TMH and TMR in CD are lacking. Consistent, validated criteria are essential to enable reproducible ultrasound endpoints, support treat-to-target strategies, and facilitate incorporation of IUS into CD clinical trials and routine care.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1707-1721"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148137973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on incidence estimates and rural ascertainment in the Kinta Valley IBD follow-up study.","authors":"Xiaohe Zhang, Chaochi Yue","doi":"10.1093/ibd/izag158","DOIUrl":"10.1093/ibd/izag158","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1862-1863"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trained immunity: An unexplored component of IBD pathogenesis.","authors":"Michael Doulberis, Stergios A Polyzos, Abbas Yadegar, Jannis Kountouras","doi":"10.1093/ibd/izag119","DOIUrl":"10.1093/ibd/izag119","url":null,"abstract":"<p><p>Trained immunity (TI) describes the capability of the innate immune system and its tissue-resident cells to acquire long-lasting functional adaptations following an initial inflammatory or microbial insult. These changes are maintained through coordinated immunometabolic rewiring and epigenetic remodeling, resulting in amplified or altered responses upon subsequent challenges. Inflammatory bowel disease (IBD) is a chronic, relapsing disorder of the gastrointestinal tract, and TI offers a useful framework for understanding disease persistence, relapse proneness, and incomplete resolution despite effective targeting of adaptive immune pathways. While TI has been extensively studies in various chronic inflammatory disorders, its role in IBD remains rather underexplored and largely confined to early preclinical evidence. Within this narrative review, we aim to address this gap by providing current insights into the potential pathogenetic mechanisms underpinning TI in IBD. We examine how the shaping of the behavior of monocytes, macrophages, and their bone marrow progenitors and how steady exposure to microbial ligands, dysbiotic metabolites, and metabolic stressors within the intestinal lumen may establish a sustained proinflammatory \"memory\" in the context of IBD. From a translational perspective, we consider how TI may favor relapse even during clinical remission and discuss its potential relevance for patient stratification, biomarker identification, and the development of novel therapeutic strategies. Ultimately, integration of TI into IBD pathophysiology may corroborate more lasting, mechanism-based approaches to remission.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1833-1842"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features and cancer-specific survival in young patients with ulcerative colitis-associated colorectal neoplasia: a nationwide cohort study in Japan.","authors":"Takahide Shinagawa, Koichi Komatsu, Motoi Uchino, Hiroki Ikeuchi, Kohei Shigeta, Shiro Oka, Daijiro Higashi, Shimpei Ogawa, Kazuhiro Watanabe, Masatsune Shibutani, Yoshiki Okita, Toshifumi Wakai, Yusuke Mizuuchi, Kinya Okamoto, Kazutaka Yamada, Yu Sato, Takayuki Ogino, Hideaki Kimura, Kenichi Takahashi, Koya Hida, Yusuke Kinugasa, Fumio Ishida, Junji Okuda, Koji Daito, Takayuki Yamamoto, Seiichiro Yamamoto, Fumikazu Koyama, Junichiro Hiro, Koji Komori, Dai Shida, Junya Arakaki, Fumihiko Fujita, Takatoshi Matsuyama, Hideki Ueno, Hiroki Ochiai, Atsuo Maemoto, Riichiro Nezu, Shin Sasaki, Eiji Sunami, Tatsuki Noguchi, Kenichi Sugihara, Yoichi Ajioka, Soichiro Ishihara","doi":"10.1093/ibd/izag069","DOIUrl":"10.1093/ibd/izag069","url":null,"abstract":"<p><strong>Background: </strong>The incidence of ulcerative colitis-associated colorectal neoplasia (UCAN) is increasing, but clinicopathological features and outcomes in young patients remain unclear. We aimed to clarify the characteristics and survival of UCAN diagnosed before the age of 40 using years in a nationwide Japanese cohort study conducted by the Japanese Society for Cancer of the Colon and Rectum.</p><p><strong>Methods: </strong>We retrospectively analyzed 1212 patients with UCAN treated at 43 institutions in Japan during the period from 1983 to 2020. Patients were categorized as young (<40 years) or non-young (≥40 years). Clinicopathological features, cancer-specific survival (CSS), relapse-free survival (RFS), and survival after recurrence (SAR) were compared.</p><p><strong>Results: </strong>Young-onset UCAN accounted for 252 patients (20.8%) and showed a shorter interval from UC onset to carcinogenesis (14.0 vs 17.0 years; P < .001), more frequent pancolitis (81.3% vs 74.8%; P = .012), and a higher proportion of poorly differentiated, mucinous, or signet-ring cell carcinoma (20.2% vs 13.3%; P < .001). Five-year CSS was significantly lower in young patients (85.1% vs 89.8%; P = .039), whereas RFS was comparable (86.2% vs 86.3%; P = .750). Minimally invasive surgery (MIS) was independently associated with improved CSS (hazard ratio [HR], 0.593; 95% CI, 0.356-0.987; P = .045). The SAR remained poor in both age groups (23.6% vs 28.5%; P = .468).</p><p><strong>Conclusions: </strong>When diagnosed in patients aged <40 years, UCAN is characterized by earlier carcinogenesis, extensive disease, and aggressive histology, with worse CSS. The potential role of MIS in improving prognosis warrants further prospective investigation, while the outcome of SAR remains poor irrespective of patient age.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1750-1759"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin-deep connections: likelihood of skin-scarring history in patients with stricturing/penetrating Crohn disease compared with patients with nonstricturing/nonpenetrating disease and non-inflammatory bowel disease controls.","authors":"Mustafa Mohamedrashed, Saiumaeswar Yogakanthi, Ayushi Chauhan, Sarah Lucas, Aaron Robinson, Mayur Garg","doi":"10.1093/ibd/izag058","DOIUrl":"10.1093/ibd/izag058","url":null,"abstract":"<p><p>Patients with stricturing/penetrating Crohn disease had significantly more hypertrophic/keloid scars than those with nonstricturing disease in this cross-sectional proof-of-concept study, suggesting potential shared fibrotic mechanisms between cutaneous and intestinal fibrosis. If corroborated in larger and more longitudinal cohorts, overcoming potential confounders such as postsurgical scars, this novel association may help identify patients at risk and facilitate development of targeted antifibrotic therapies.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1843-1848"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trained immunity: Breaking a dogma and a missing opportunity in IBD?","authors":"Claudio Fiocchi, Dimitrios Iliopoulos","doi":"10.1093/ibd/izag115","DOIUrl":"10.1093/ibd/izag115","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1854-1856"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel SLC10A2 variants induce primary bile acid malabsorption and dysbiosis with IBD-like features.","authors":"Casey R Johnson, Lily Gillette, Qurbonali Qurbonov, Abigail Plone, Stefanie S Schmieder, Michael Anderson, Katie Cibelli, Yanjia Jason Zhang, Krishnan Raghunathan, Michael Field, Alka Goyal, Stacy A Kahn, Scott B Snapper, Jocelyn A Silvester, Jay R Thiagarajah","doi":"10.1093/ibd/izag137","DOIUrl":"10.1093/ibd/izag137","url":null,"abstract":"<p><p>We describe biochemically and functionally validated primary bile acid malabsorption caused by novel biallelic SLC10A2 variants in a child initially diagnosed with Crohn's disease. Pediatric IBD cohort reanalysis identified PBAM-compatible genotypes, supporting selective testing when clinical features are suggestive.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1849-1853"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging-based prediction of biologic failure in perianal Crohn's disease: the emerging role of 3D transrectal ultrasound.","authors":"Zeinab Bakhshi, Ritika Kumari, Jalpa Devi","doi":"10.1093/ibd/izag125","DOIUrl":"10.1093/ibd/izag125","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1859-1861"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.","authors":"Kwestan Safari, Wei Jen Ma, Prabhreet Sekhon, Priya Rai, Susan C Menzies, Tomoaki Hoshino, Anne-Sophie Fratzscher, Andrew Roth, Karen Madsen, Laura M Sly","doi":"10.1093/ibd/izag127","DOIUrl":"10.1093/ibd/izag127","url":null,"abstract":"<p><strong>Background: </strong>Crohn disease is a chronic, immune-mediated disease that can lead to intestinal fibrosis, strictures, and bowel obstruction. The Src homology 2 domain-containing inositol polyphosphate 5'-phosphatase-deficient (SHIP-/-) mouse develops spontaneous Crohn disease-like ileal inflammation and fibrosis. Fibrosis depends on increased phosphatidylinositol 3-kinase p110δ activity downstream of interleukin 4 (IL-4) or IL-13. Because current anti-inflammatory treatments do not prevent or reverse fibrosis, we aimed to identify the key cytokine(s) and its cellular source(s).</p><p><strong>Methods: </strong>We blocked IL-4 or IL-13 in mice by use of neutralizing antibodies or genetic ablation. Intestinal inflammation and fibrosis were assessed by gross pathology, histopathology, collagen accumulation, muscle thickening, immune cell infiltration, and tissue IL-1β concentrations. IL13 and its cellular source in stricturing Crohn disease were examined using single-cell RNA sequencing and RNAscope. Mast cells and Il13 were also assessed in ileal cross-sections from SHIP+/+ and SHIP-/- mice.</p><p><strong>Results: </strong>Blocking or genetic ablation of IL-13, but not IL-4, significantly reduced ileal fibrosis in mice, including collagen accumulation, smooth muscle thickening, vimentin + cells, and proliferating vimentin + cells. Blockade of IL-13 also reduced intestinal inflammation, including immune cell infiltration and ileal IL-1β concentrations. Single-cell RNA-sequencing analyses identified mast cells as the exclusive source of IL13 in stricturing Crohn disease. Human resection tissues confirmed increased mast cells in diseased small intestine and identified mast cells as the source of IL13. SHIP-/- mice similarly showed increased ileal mast cells that were also a source of IL13.</p><p><strong>Conclusions: </strong>IL-13 is critical for intestinal fibrosis in SHIP-deficient mice, and mast cells are a source of IL13 in Crohn disease-associated intestinal fibrosis.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1783-1799"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis.","authors":"Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy","doi":"10.1093/ibd/izag032","DOIUrl":"10.1093/ibd/izag032","url":null,"abstract":"<p><strong>Background: </strong>Janus kinase (JAK) inhibitors are effective oral therapies for inflammatory bowel disease (IBD). While acne is a known adverse event in dermatological cohorts, its incidence and risk factors in the IBD population are not well-defined. We aimed to determine the pooled incidence of acne in IBD patients treated with JAK inhibitors and to explore this risk across key clinical subgroups.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines. MEDLINE, EMBASE, and CENTRAL were searched from inception to September 2025 for randomized controlled trials (RCTs) and observational studies reporting acne incidence in IBD patients on JAK inhibitors. Data were pooled using a random-effects generalized linear mixed-effects model. Pre-specified subgroup analyses were performed.</p><p><strong>Results: </strong>A total of 50 studies (5 RCTs, 45 observational) involving 9902 IBD patients were included. The overall pooled incidence of acne was 8.6% (95% CI: 6.4%-11.6%). Acne rates were significantly higher (P < .0001) with the upadacitinib (12.2%), compared to tofacitinib (2.6%) and filgotinib (2.3%). A numerically higher incidence was observed during induction (8.6%) versus maintenance (4.2%) therapy, though this difference was not statistically significant (P = .07). The incidence was significantly higher in the pediatric population (12.2%) compared to adults (7.4%) (P = .03). In RCTs, JAK inhibitors were associated with significantly increased odds of acne compared to placebo (OR 2.43, 95% CI: 1.33-4.43, P = .019). No statistically significant difference was observed by IBD subtype.</p><p><strong>Conclusion: </strong>Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1800-1814"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}